Wright State University Boonshoft School of Medicine, Fairborn, OH; Ohio Pain Clinic, Dayton, OH.
Dartmouth College Geisel School of Medicine, Hanover, NH.
Pain Physician. 2022 Aug;25(5):381-386.
In the United States, the prevalence of opioid use disorders has increased in recent years along with an attendant rise in the incidence of chronic pain disorders and prescription opioid use. Patient navigation services have been used to improve health outcomes in cancer and other chronic disease states, but it is unclear whether the implementation of patient navigation services can facilitate improved outcomes among patients receiving chronic opioid therapy.
The objective of this study was to compare the outcomes of patients receiving chronic opioid therapy plus patient navigation services and those receiving chronic opioid therapy as a part of usual care.
This was a prospective, observational study. Consecutive patients receiving chronic opioid therapy were enrolled, with alternating assignments to patient navigation (n = 30) or usual care (n = 30). Participants in the patient navigation group received support from a non-physician, non-advanced practice provider staff member who initiated frequent contact via telephone, telemedicine, or in-clinic visits to discuss the patient's health goals. The minimum follow-up period was 90 days. Outcomes qualitatively compared across groups included final pain score, final morphine milligram equivalent (MME) per day, and discharge rates. Risk factors for discharge within the navigation group were assessed. Patient feedback was also solicited.
This study was conducted at a single independent pain clinic in the United States.
Demographic features were similar between the navigator group and the control group. The control group had a higher average initial pain score (7.0/10) than the intervention group (5.9/10) and were receiving a higher initial dose of opioids (23.1 vs 19.0 MME/d). After an average follow-up of 108.7 days, patients in the navigator group had a 16% decrease in final opioid dose compared with a 23% increase in the control group. Furthermore, patients in the control group were discharged from the practice at a higher rate (23.3% vs 6.6%), suggesting increased opioid misuse in the control group compared with the navigator group. In the navigator group, higher levels of anxiety and depression were the primary predictors of discharge.
This was a single-center study with a small sample size. The generalizability of these results to other clinic settings is unknown.
Patient navigation decreased opioid use and practice discharge compared with usual care in an independent pain clinic, suggesting a role for patient navigation in reducing opioid misuse and potentially reducing adverse events.
近年来,美国阿片类药物使用障碍的患病率有所增加,同时慢性疼痛障碍和处方类阿片类药物的使用也有所上升。患者导航服务已被用于改善癌症和其他慢性疾病患者的健康结果,但尚不清楚实施患者导航服务是否可以促进接受慢性阿片类药物治疗的患者的结果改善。
本研究旨在比较接受慢性阿片类药物治疗加患者导航服务的患者和接受慢性阿片类药物治疗作为常规护理一部分的患者的结局。
这是一项前瞻性、观察性研究。连续入组接受慢性阿片类药物治疗的患者,交替分配给患者导航(n=30)或常规护理(n=30)。患者导航组的参与者接受非医师、非高级实践提供者工作人员的支持,他们通过电话、远程医疗或门诊就诊频繁联系,讨论患者的健康目标。最低随访期为 90 天。对两组之间的定性比较结果包括最终疼痛评分、最终吗啡毫克当量(MME)/天和出院率。评估了导航组内出院的风险因素。还征求了患者的反馈意见。
这项研究在美国一家独立的疼痛诊所进行。
导航组和对照组的人口统计学特征相似。对照组的平均初始疼痛评分(7.0/10)高于干预组(5.9/10),初始阿片类药物剂量也较高(23.1 vs 19.0 MME/d)。平均随访 108.7 天后,导航组患者的最终阿片类药物剂量下降了 16%,而对照组患者的最终阿片类药物剂量增加了 23%。此外,对照组患者的出院率较高(23.3% vs 6.6%),这表明对照组患者的阿片类药物滥用率高于导航组。在导航组中,较高的焦虑和抑郁水平是主要的出院预测因素。
这是一项单中心研究,样本量较小。这些结果在其他诊所环境中的推广性尚不清楚。
与常规护理相比,患者导航在独立疼痛诊所减少了阿片类药物的使用和实践出院,这表明患者导航在减少阿片类药物滥用和潜在减少不良事件方面发挥了作用。